The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue … [Read More...] about NIH launches effort to combat type 2 diabetes in young people
Main Content
Drug Tech
Today on Drug Delivery Business
- NIH launches effort to combat type 2 diabetes in young people
- Glooko announces CEO transition with $100M financing
- Clearside Biomedical’s drug-device combo study meets endpoints
- Trinity Biotech completes pre-pivotal study of next-gen CGM
- Medinol has first human implant of drug-eluting peripheral stent in Australia
- BD partners with ten23 health on prefilled syringe manufacturing
- ApiJect Systems promotes COO from within
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
NIH launches effort to combat type 2 diabetes in young people
By Sean Whooley
The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue … [Read More...] about NIH launches effort to combat type 2 diabetes in young people
Glooko announces CEO transition with $100M financing
By Sean Whooley
Glooko announced today that it secured $100 million in a financing round and appointed Mike Alvarez as its new CEO. Russ Johannesson said on LinkedIn that he stepped down from the CEO post at Glooko. He held the corner office for six-and-a-half … [Read More...] about Glooko announces CEO transition with $100M financing
Trinity Biotech completes pre-pivotal study of next-gen CGM
By Sean Whooley
Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM technology. The study assessed the analytical performance of continuous glucose monitoring (CGM) technology enhancements … [Read More...] about Trinity Biotech completes pre-pivotal study of next-gen CGM
BD partners with ten23 health on prefilled syringe manufacturing
By Sean Whooley
BD (NYSE:BDX) announced today that it entered into a collaboration with ten23 health to develop a new way to track prefillable syringes (PFS). ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute … [Read More...] about BD partners with ten23 health on prefilled syringe manufacturing
Medtronic recalls some MiniMed automated insulin delivery systems with battery issues
By Sean Whooley
Medtronic (NYSE:MDT) today announced a voluntary recall warning of battery issues with its MiniMed 600 and 700 series insulin pumps. FDA deemed the recall Class I, the most serious kind. The medtech giant issued a field action starting on July … [Read More...] about Medtronic recalls some MiniMed automated insulin delivery systems with battery issues
MannKind has more positive inhaled insulin data
By Sean Whooley
MannKind announced top-level 30-week results from its Phase 4 INHALE-3 study comparing inhaled insulin to traditional delivery methods. The Danbury, Connecticut-based company designed Afrezza, a rapid-acting inhaled human insulin, to improve … [Read More...] about MannKind has more positive inhaled insulin data
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
By Sean Whooley
Qnovia announced that the FDA cleared its investigational new drug (IND) application for the RespiRx smoking cessation inhaler (QN-01). RespiRx, a drug-device combination product, offers inhalable nicotine replacement therapy (NRT) to assist in … [Read More...] about Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
By Sean Whooley
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S. Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes … [Read More...] about Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
Stevanato Group expands large-volume drug delivery offerings
By Sean Whooley
Stevanato Group announced today that it expanded the capacity of its Vertiva on-body device for subcutaneous large-volume drug delivery. The Italy-based company says its Vertiva platform now covers 10mL volumes. It plans to present the latest … [Read More...] about Stevanato Group expands large-volume drug delivery offerings
Vivani can begin first-in-human GLP-1 implant trial in Australia following regulatory approval
By Sean Whooley
Vivani Medical (Nasdaq:VANI) today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 implant. The LIBERATE-1 trial will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight … [Read More...] about Vivani can begin first-in-human GLP-1 implant trial in Australia following regulatory approval
In case you missed it
- Dexcom, Retta, Beyond Type 2 team up to raise glucose awareness
- Ypsomed reports positive outcomes with automated insulin delivery for maternal health
- Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
- Phillips Medisize to buy inhaled drug delivery device maker Vectura from Philip Morris
- Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
- BD launches new prefillable syringe, expands platform capacity
- Senseonics wins FDA nod for 365-day implantable CGM
- Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
- Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
- Orange Biomed to showcase microfluidic-based A1C test
- Dexcom CGM worn in outer space on Polaris Dawn mission
- Elutia announces first implant of drug-eluting bioenvelope for pacemakers and neurostimulators
- Abbott launches Lingo over-the-counter CGM biosensor in the U.S.
- Beta Bionics to pair bionic pancreas with Abbott FreeStyle Libre 3 Plus
- Embecta wins FDA clearance for disposable insulin patch pump
Clinical Trials
NIH launches effort to combat type 2 diabetes in young people
The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue moving forward. It aims to advance understanding of the biologic, social, and environmental […]
Clearside Biomedical’s drug-device combo study meets endpoints
Clearside Biomedical (Nasdaq:CLSD) today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary outcomes. Alpharetta, Georgia-based Clearside develops the SCS Microinjector suprachoroidal injection device. It enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to […]
Trinity Biotech completes pre-pivotal study of next-gen CGM
Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM technology. The study assessed the analytical performance of continuous glucose monitoring (CGM) technology enhancements implemented by Trinity. Dublin, Ireland-based Trinity added the improvements to the CGM technology it acquired from Waveform Technologies in January. Trinity implemented an […]
Medinol has first human implant of drug-eluting peripheral stent in Australia
Medinol today announced the successful first-in-human implantation of its ChampioNIR drug-eluting peripheral stent. Dr. Gerard S. Goh and Dr. Thodur Vasudevan of the Alfred Hospital in Melbourne, Australia, completed the stent implant. The company says it introduces a “revolutionary advancement” in the mechanics, durability and drug delivery of peripheral drug-eluting stents. Tel Aviv, Israel-based Medinol […]
MannKind has more positive inhaled insulin data
MannKind announced top-level 30-week results from its Phase 4 INHALE-3 study comparing inhaled insulin to traditional delivery methods. The Danbury, Connecticut-based company designed Afrezza, a rapid-acting inhaled human insulin, to improve glycemic control in adults with type 1 diabetes mellitus. The INHALE-3 study looks at Afrezza against usual care. Mannkind defines usual care as multiple […]